1. Home
  2. CINGW vs WINA Comparison

CINGW vs WINA Comparison

Compare CINGW & WINA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • WINA
  • Stock Information
  • Founded
  • CINGW N/A
  • WINA 1988
  • Country
  • CINGW United States
  • WINA United States
  • Employees
  • CINGW 13
  • WINA N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • WINA Other Specialty Stores
  • Sector
  • CINGW Health Care
  • WINA Consumer Discretionary
  • Exchange
  • CINGW Nasdaq
  • WINA Nasdaq
  • Market Cap
  • CINGW N/A
  • WINA N/A
  • IPO Year
  • CINGW 2021
  • WINA 1993
  • Fundamental
  • Price
  • CINGW $0.05
  • WINA $417.67
  • Analyst Decision
  • CINGW
  • WINA Strong Buy
  • Analyst Count
  • CINGW 0
  • WINA 1
  • Target Price
  • CINGW N/A
  • WINA $445.00
  • AVG Volume (30 Days)
  • CINGW N/A
  • WINA 19.1K
  • Earning Date
  • CINGW N/A
  • WINA 10-16-2024
  • Dividend Yield
  • CINGW N/A
  • WINA 0.64%
  • EPS Growth
  • CINGW N/A
  • WINA N/A
  • EPS
  • CINGW N/A
  • WINA 10.93
  • Revenue
  • CINGW N/A
  • WINA $81,781,000.00
  • Revenue This Year
  • CINGW N/A
  • WINA $0.47
  • Revenue Next Year
  • CINGW N/A
  • WINA $4.86
  • P/E Ratio
  • CINGW N/A
  • WINA $37.39
  • Revenue Growth
  • CINGW N/A
  • WINA N/A
  • 52 Week Low
  • CINGW N/A
  • WINA $330.25
  • 52 Week High
  • CINGW N/A
  • WINA $451.30
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • WINA 60.80
  • Support Level
  • CINGW N/A
  • WINA $386.88
  • Resistance Level
  • CINGW N/A
  • WINA $430.00
  • Average True Range (ATR)
  • CINGW 0.00
  • WINA 10.80
  • MACD
  • CINGW 0.00
  • WINA 0.60
  • Stochastic Oscillator
  • CINGW 0.00
  • WINA 74.05

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: